SCHEMBL2193790

SCHEMBL2193790

Cc1ccc(CN(I)I)cc1.Cn1nc(-c2ccccc2)[nH]c1=[Pt]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.38
POLB P06746 3/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PIM1 P11309 1/20 0.36
MARK3 P27448 1/20 0.36
GSK3B P49841 1/20 0.36
PRKAA1 Q13131 1/20 0.36
TAOK1 Q7L7X3 1/20 0.36
PIM3 Q86V86 1/20 0.36
PBK Q96KB5 1/20 0.36
SRPK1 Q96SB4 1/20 0.36
MAP4K5 Q9Y4K4 1/20 0.36
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
CYP2C19 P33261 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197165 0.92 CSF1R (0.38) CSF1RMAPTKDM4EALDH1A1LMNA
SCHEMBL2193102 0.89 ALOX5 (0.40) CYP19A1NPC1SMN1; SMN2CSF1RMAPT
SCHEMBL2193608 0.89 MAPK13 (0.36) CSF1RNPSR1NR1H2NR1H3MAPT
SCHEMBL2194610 0.89 CYP19A1 (0.37) CYP19A1PIM1SMN1; SMN2CSF1RNR1H2
SCHEMBL2192771 0.87 LMNA (0.33) CSF1RKDM4EMEN1GAAKMT2A
SCHEMBL2195584 0.86 CXCR2 (0.38) CYP19A1POLBNPSR1KDM4EMEN1
SCHEMBL2199132 0.83 CYP2C19 (0.36) CYP19A1POLBPRKD3MAP4K4PIM1
SCHEMBL2195930 0.77 GAA (0.34) SMN1; SMN2MAPTKDM4EALDH1A1GAA
SCHEMBL2197023 0.74 CYP19A1 (0.39) CYP19A1POLBNPC1RAB9ACYP2C19
SCHEMBL2196817 0.74 NR1H2 (0.36) POLBGSK3BSMN1; SMN2NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885POLB 760/4885PRKD3 1710/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 CYP19A1 787/4885POLB 760/4885PRKD3 1710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.